基于糖酵解-免疫相关基因的急性髓系白血病患者预后特征。
The prognostic signature based on glycolysis-immune related genes for acute myeloid leukemia patients.
机构信息
Department of Pediatric Hematology and Oncology, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010020, China.
Department of Nuclear Medicine, Peking University Cancer Hospital, Inner Mongolia and Affiliated Cancer Hospital of Inner Mongolia Medical University, Huhhot 010020, Inner Mongolia Autonomous Region, China.
出版信息
Immunobiology. 2023 May;228(3):152355. doi: 10.1016/j.imbio.2023.152355. Epub 2023 Feb 21.
Acute myeloid leukemia (AML) is widely considered an immunoresponsive malignancy. However, potential association between glycolysis-immune related genes and AML patients' prognosis has been seldom studied. AML-related data was downloaded from TCGA and GEO databases. We grouped patients according to Glycolysis status, Immune Score and combination analysis, basing on which overlapped differentially expressed genes (DEGs) were identified. The Risk Score model was then established. The results showed that totally 142 overlapped genes were probably correlated with glycolysis-immunity in AML patients, among which 6 optimal genes were screened to construct Risk Score. High Risk Score was an independent poor prognostic factor for AML. In conclusion, we established a relatively reliable prognostic signature of AML based on glycolysis-immunity related genes, including METTL7B, HTR7, ITGAX, TNNI2, SIX3 and PURG.
急性髓系白血病（AML）被广泛认为是一种免疫反应性恶性肿瘤。然而，糖酵解-免疫相关基因与 AML 患者预后之间的潜在关联很少被研究。我们从 TCGA 和 GEO 数据库下载了 AML 相关数据。我们根据糖酵解状态、免疫评分和组合分析对患者进行分组，在此基础上确定了重叠的差异表达基因（DEGs）。然后建立风险评分模型。结果表明，在 AML 患者中，共有 142 个重叠基因可能与糖酵解-免疫相关，其中筛选出 6 个最优基因构建风险评分。高风险评分是 AML 的独立不良预后因素。总之，我们基于糖酵解-免疫相关基因建立了一个相对可靠的 AML 预后标志物，包括 METTL7B、HTR7、ITGAX、TNNI2、SIX3 和 PURG。
Zotero 插件